Adverum Biotechnologies, Inc.

Biotechnology • Healthcare • Redwood City, CA, United States • ADVM (NCM)

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Ray Therapeutics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

650 656 9323 100 Cardinal Way, Redwood City, CA 94063, United States Wikipedia

Stock Performance (90 Days)

Data through Dec 9, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Lilly to Acquire Adverum Biotechnologies - PR Newswire

PR Newswire • Oct 24

Eli Lilly to acquire Adverum Biotechnologies - Ophthalmology Times

Ophthalmology Times • Oct 30

Adverum, hammered by gene therapy downturn, sells to Lilly in unusual deal - BioPharma Dive

BioPharma Dive • Oct 24

Adverum Biotechnologies (NASDAQ:ADVM) Lowered to "Strong Sell" Rating by Wall Street Zen - MarketBeat

MarketBeat • Dec 13

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) institutional owners may be pleased with recent gains after 28% loss over the past year - Yahoo Finance

Yahoo Finance • Oct 3

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Adverum Biotechnologies, Inc. had layoffs?

No layoff events have been recorded for Adverum Biotechnologies, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Adverum Biotechnologies, Inc. have?

Adverum Biotechnologies, Inc. has approximately 155 employees.

What industry is Adverum Biotechnologies, Inc. in?

Adverum Biotechnologies, Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is Adverum Biotechnologies, Inc. a publicly traded company?

Yes, Adverum Biotechnologies, Inc. is publicly traded under the ticker symbol ADVM on the NCM. The company has a market capitalization of approximately $0.10 billion.

Where is Adverum Biotechnologies, Inc. headquartered?

Adverum Biotechnologies, Inc. is headquartered in Redwood City, CA, United States at 100 Cardinal Way, Redwood City, CA 94063, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.